Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations.

[1]  F. Drago,et al.  Porphyrin Elevation in a Patient on Treatment With Simeprevir: Could It Be a Possible Explanation for Simeprevir-Associated Photosensitivity? , 2016, The American Journal of Gastroenterology.

[2]  F. Favata,et al.  A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma. , 2016, Journal of pharmaceutical and biomedical analysis.

[3]  S. Pungpapong,et al.  Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis , 2015, Hepatology.

[4]  V. Soriano,et al.  Dual antiviral therapy for HIV and hepatitis C – drug interactions and side effects , 2015, Expert opinion on drug safety.

[5]  S. Ouwerkerk-Mahadevan,et al.  Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment , 2015, Drugs in R&D.

[6]  G. di Perri,et al.  Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  Brian L. Pearlman,et al.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study , 2014, The Lancet.

[8]  M. Rizzetto,et al.  Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. , 2014, Antiviral research.

[9]  A. D’Avolio,et al.  Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir , 2014, Journal of viral hepatitis.

[10]  J. Pawlotsky.  New Hepatitis C Therapies , 2014, Seminars in Liver Disease.

[11]  M. Rizzetto,et al.  Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single‐nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4 , 2011, Hepatology.

[12]  C. la Vecchia,et al.  Metabolic Syndrome Is Also a Risk Factor for Primary Liver Cancer in Patients Younger than 65 Years of Age? , 2011, Hepatology.

[13]  V. Soriano,et al.  Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. , 2008, The Journal of antimicrobial chemotherapy.

[14]  C. Trépo,et al.  Prediction of Sustained Virological Response by Ribavirin Plasma Concentration at Week 4 of Therapy in Hepatitis C virus Genotype 1 Patients , 2008, Antiviral therapy.

[15]  P. Marquet,et al.  Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C , 2008, Hepatology.

[16]  G. di Perri,et al.  Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.